Thomas C. Shea
School of Medicine
Bone Marrow and Stem Cell Transplantation Program
Leukemia, Lymphoma, and Myeloma Program
Area of interest
UNC has performed over 900 autologous and allogeneic related and unrelated donor transplants and has recently completed a trial measuring drug levels of IV busulfan for targeting individualized dosing of this agent when given by continuous infusion. Additional trials have examined the role of G-CSF stimulated bone marrow for allogeneic transplants and the role of amifostene and keratinocyte growth factor in reducing the mouth sores which patients experience when undergoing an autologous transplant.
UNC is a main member of CALGB and has also received a Minority Initiative Program award from the NCI for facilitation of enrollment of minority patients onto CALGB trials.
Dr. Shea has served on the Executive Committee of the North American and International Bone Marrow Transplant Registry. He is also vice chair of the CALGB Transplant Committee, a member of the CALGB LYmphoma Committee and is a member of the Advisory Committees for several pharmaceutical companies. He chairs a CALGB study examining the role of transplantation as consolidation for aggressive non-Hodgkin's Lymphoma and a second recently completed CALGB study with non-ablative allogeneic transplants for low grade lymphoma and chronic lymphoid leukemia.